Quhill, F. and Beiderbeck, A. (2017) “Cost Advantage of Fluocinolone Acetonide Implant (ILUVIEN®) versus Ranibizumab in the Treatment of Chronic Diabetic Macular Oedema”, Global and Regional Health Technology Assessment, 4(1), pp. 155–164. doi: 10.33393/grhta.2017.391.